Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma. Ma L, Zhu M, Li G, Gai J, et al. Respir Res 2022;23:316.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ma L, Zhu M, Li G, Gai J, et al. Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma. Respir Res 2022;23:316.
PMID: 36403040